TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35209981

Group type: EXPERIMENTAL
Intervention: Preterm infants (various groups based on gestational age)
Number of subjects: 2146

Group type: EXPERIMENTAL
Intervention: Preterm infants (various groups based on birth weight)
Number of subjects: 2146

Group type: EXPERIMENTAL
Intervention: Preterm infants (various groups based on blood collection time)
Number of subjects: 2146
Study: 34260175

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4mg
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Tadalafil 10mg
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 32135138

Group type: EXPERIMENTAL
Intervention: Exenatide (10 μg subcutaneous injection three times daily for 26 weeks)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo (subcutaneous injection three times daily for 26 weeks)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 33624377

Group type: EXPERIMENTAL
Intervention: Baseline lung cancer stigma (measured by Cataldo Lung Cancer Stigma Scale)
Number of subjects: 194
Study: 34592951

Group type: EXPERIMENTAL
Intervention: SMART design
Number of subjects: 100

Group type: COMPARATOR
Intervention: RCT design
Number of subjects: 100
Study: 32042406

Group type: EXPERIMENTAL
Intervention: Food products designed to reduce appetite
Number of subjects: 181

Group type: COMPARATOR
Intervention: Matching controls
Number of subjects: 181
Study: 34873002

Group type: EXPERIMENTAL
Intervention: right@home Nurse Home Visiting (NHV) programme
Number of subjects: 722

Group type: COMPARATOR
Intervention: usual care (clinic visits)
Number of subjects: 722
Study: 33066893

Group type: EXPERIMENTAL
Intervention: Aspirin plus clopidogrel (dual antiplatelet therapy)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Aspirin monotherapy
Number of subjects: 1000
Study: 35963028

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 33423267

Group type: EXPERIMENTAL
Intervention: CYP2C19 gene polymorphisms (specifically AG, GG genotypes and A allele of rs4986893 locus)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: CYP3A5 gene polymorphisms (specifically GG genotype and G allele of rs776746 locus)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: CYP2C19 gene polymorphisms (specifically GG genotype of rs4986893 locus)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: CYP3A5 gene polymorphisms (specifically AA and AG genotypes of rs776746 locus)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Statistical power of the study
Number of subjects: 1000
Study: 34608851

Group type: EXPERIMENTAL
Intervention: Ergonomic welding torch
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional welding torch
Number of subjects: 10
Study: 34479613

Group type: EXPERIMENTAL
Intervention: Yijinjing combined with Tuina
Number of subjects: 102

Group type: COMPARATOR
Intervention: Tuina
Number of subjects: 102
Study: 35623152

Group type: EXPERIMENTAL
Intervention: Binaural Beats (BB) intervention starting 5 minutes before and continuing until the end of the colonoscopy procedure.
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group (no Binaural Beats), routine nursing care only.
Number of subjects: 115
Study: 32712674

Group type: EXPERIMENTAL
Intervention: WISCA utilization for empiric antibiotic prescription
Number of subjects: 6849

Group type: COMPARATOR
Intervention: Control group (no WISCA utilization)
Number of subjects: 6849
Study: 35012783

Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 plus bevacizumab 15 mg/kg intravenously every 3 weeks for 3 cycles (bevacizumab arm)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Concurrent thoracic radiotherapy (TRT) 45 Gy in 25 fractions (TRT arm)
Number of subjects: 82
Study: 32142578

Group type: EXPERIMENTAL
Intervention: Guided Bone Regeneration (GBR)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (native bone)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 45
Study: 33572825

Group type: EXPERIMENTAL
Intervention: Rice germ supplementation (25 g twice a day for 4 weeks)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 32315112

Group type: EXPERIMENTAL
Intervention: mpMRI-targeted biopsy (TBx)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: CUDI-targeted biopsy (TBx)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Systematic biopsy (SBx)
Number of subjects: 150
Study: 35767970

Group type: EXPERIMENTAL
Intervention: Jollab (saffron-based beverage) 20 mL three times daily for 4 weeks
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo 20 mL three times daily for 4 weeks
Number of subjects: 75
Study: 33165594

Group type: EXPERIMENTAL
Intervention: Family Spirit Nurture (FSN) intervention
Number of subjects: 134

Group type: COMPARATOR
Intervention: Injury prevention education control
Number of subjects: 134
Study: 32921111

Group type: EXPERIMENTAL
Intervention: Attention and Interpretation Therapy (AIT) for 10 weeks
Number of subjects: 200

Group type: COMPARATOR
Intervention: Routine intervention measures (Control)
Number of subjects: 200
Study: 32239984

Group type: EXPERIMENTAL
Intervention: Mild cleanser and moisturizer used twice daily for two weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: Mild cleanser without moisturizer
Number of subjects: 52
Study: 34262611

Group type: EXPERIMENTAL
Intervention: Sodium picosulfate, magnesium oxide, and citric acid (SPMC) oral solution bowel preparation
Number of subjects: 0
Study: 36302983

Group type: EXPERIMENTAL
Intervention: Preservation rhinoplasty (PR)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Structural rhinoplasty (SR)
Number of subjects: 34
Study: 33530186

Group type: EXPERIMENTAL
Intervention: Improved sitting Wuqinxi intervention
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standardized comprehensive western medicine treatment and routine care
Number of subjects: 160
Study: 32621885

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH), median duration 6.2 months (IQR 2.5-12.7)
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Warfarin, median duration 2.2 years (IQR 0.9-7.1)
Number of subjects: 383

Group type: COMPARATOR
Intervention: No anticoagulation
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Secondary thromboprophylaxis with LMWH
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Secondary thromboprophylaxis with warfarin
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: LMWH
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 383
Study: 34256147

Group type: EXPERIMENTAL
Intervention: PEG 2+2L+bisacodyl
Number of subjects: 196

Group type: COMPARATOR
Intervention: PEG 4+2L+bisacodyl
Number of subjects: 196
Study: 33600761

Group type: EXPERIMENTAL
Intervention: Endoscopic nasopharyngectomy (ENPG)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Intensity-modulated radiotherapy (IMRT)
Number of subjects: 200

Group type: COMPARATOR
Intervention: IMRT
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: ENPG
Number of subjects: 200
Study: 33370133

Group type: EXPERIMENTAL
Intervention: OurRelationship (OR) program
Number of subjects: 742

Group type: EXPERIMENTAL
Intervention: ePREP program
Number of subjects: 742

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 742

Group type: EXPERIMENTAL
Intervention: Negative communication improvements
Number of subjects: 742

Group type: EXPERIMENTAL
Intervention: All mechanisms improvements
Number of subjects: 742
Study: 34437308

Group type: EXPERIMENTAL
Intervention: Informed Patient-Centered (IPC) decisions
Number of subjects: 854

Group type: EXPERIMENTAL
Intervention: Informed Patient-Centered (IPC) decisions for knee patients
Number of subjects: 854

Group type: EXPERIMENTAL
Intervention: Informed Patient-Centered (IPC) decisions for hip patients
Number of subjects: 854
Study: 36411479

Group type: EXPERIMENTAL
Intervention: Esketamine-propofol
Number of subjects: 114

Group type: COMPARATOR
Intervention: Dexmedetomidine-propofol
Number of subjects: 114
Study: 33961115

Group type: EXPERIMENTAL
Intervention: Brief cognitive-behavioral group-intervention (GCBT)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Standard-length cognitive-behavioral group-intervention (GCBT)
Number of subjects: 313

Group type: COMPARATOR
Intervention: GCBT
Number of subjects: 313
Study: 34176196

Group type: EXPERIMENTAL
Intervention: Superficial cryotherapy using DMEP in three freeze–thaw cycles of 5 s each
Number of subjects: 80

Group type: COMPARATOR
Intervention: Microneedling
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Superficial cryotherapy using DMEP
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 80
Study: 32375705

Group type: EXPERIMENTAL
Intervention: Baseline-adjusted proportional odds logistic regression models
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional methods (t-tests, Wilcoxon tests)
Number of subjects: 0
Study: 35874678

Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 34499109

Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy (AT)
Number of subjects: 393

Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 393
Study: 35152531

Group type: EXPERIMENTAL
Intervention: Topical flutamide plus 5% minoxidil
Number of subjects: 40

Group type: COMPARATOR
Intervention: Topical 5% minoxidil
Number of subjects: 40
Study: 33675203

Group type: EXPERIMENTAL
Intervention: Virtual Interactive Practice to build Expertise using Real cases (VIPER) with 9 hours of supervised deliberate practice
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (residents)
Number of subjects: 40
Study: 34330882

Group type: EXPERIMENTAL
Intervention: Pictorial warnings
Number of subjects: 661

Group type: COMPARATOR
Intervention: Text-only warnings
Number of subjects: 661
Study: 35236353

Group type: EXPERIMENTAL
Intervention: Intervention: Physician office reception staff inviting patients to register on a tablet in the waiting room.
Number of subjects: 13562

Group type: COMPARATOR
Intervention: Control: Usual care without the intervention.
Number of subjects: 13562
Study: 32412872

Group type: EXPERIMENTAL
Intervention: Formal attire
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: White dress shirt with black pants
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: White casual shirt with khaki pants
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Surgical scrubs
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: White casual shirt with jeans
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Surgical scrub top with jeans
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Surgical scrub top with khaki pants
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: White laboratory coat with khaki pants
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Model veterinarian gender
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Participant education level
Number of subjects: 449
Study: 36336249

Group type: EXPERIMENTAL
Intervention: Low dose digital health intervention (1 session)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: High dose digital health intervention (12 sessions)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 74
Study: 32968933

Group type: EXPERIMENTAL
Intervention: AI-assisted colonoscopy
Number of subjects: 150

Group type: COMPARATOR
Intervention: Traditional colonoscopy
Number of subjects: 150
Study: 32756067

Group type: EXPERIMENTAL
Intervention: Gamified cognitive training (CT) intervention for 12 weeks
Number of subjects: 41

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 41
Study: 35449109

Group type: EXPERIMENTAL
Intervention: TCY‐MIT combined with CRTs (30 min per day, 6 days per week, for 3 weeks)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Conventional rehabilitation therapies (CRTs) (40 min per day, 6 days per week, for 3 weeks)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: TCY‐MIT combined with CRTs
Number of subjects: 78
Study: 32935270

Group type: EXPERIMENTAL
Intervention: Early cholecystectomy
Number of subjects: 247

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 247
Study: 32047010

Group type: EXPERIMENTAL
Intervention: Web-based decision aid (PDA)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 186
Study: 35399576

Group type: EXPERIMENTAL
Intervention: Intermittent chest tube clamping
Number of subjects: 180

Group type: COMPARATOR
Intervention: Continuous gravity drainage
Number of subjects: 180
Study: 34021173

Group type: EXPERIMENTAL
Intervention: Interactive embodied avatar VR
Number of subjects: 24

Group type: COMPARATOR
Intervention: Passive VR (no avatar and no interactivity)
Number of subjects: 24
Study: 35925914

Group type: EXPERIMENTAL
Intervention: Anakinra plus optimized standard of care (oSOC)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Optimized standard of care (oSOC) alone
Number of subjects: 71
Study: 34724631

Group type: EXPERIMENTAL
Intervention: Diarrhea prevalence
Number of subjects: 576
Study: 33017120

Group type: EXPERIMENTAL
Intervention: Collagen cross-linking (CXL)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (placebo treatment)
Number of subjects: 42
Study: 32365251

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 1102

Group type: COMPARATOR
Intervention: Ustekinumab 45/90 mg
Number of subjects: 1102
Study: 32130991

Group type: EXPERIMENTAL
Intervention: Lateral double incisions group
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Medial and lateral incisions group
Number of subjects: 41

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 41
Study: 35850110

Group type: EXPERIMENTAL
Intervention: Endurance exercise intervention (moderate- and vigorous-intensity levels)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Strength exercise intervention (moderate- and vigorous-intensity levels)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Non-active control group
Number of subjects: 36
Study: 33473026

Group type: EXPERIMENTAL
Intervention: Triple combination technique (acute normovolemic hemodilution, retrograde autologous priming, integrated arterial filter oxygenator)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard cardiopulmonary bypass technique
Number of subjects: 300
Study: 32465897

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT)
Number of subjects: 81
Study: 34801263

Group type: EXPERIMENTAL
Intervention: Occult lymph node metastasis (LNM) in patients with clinical T1 through T2 N0 esophageal cancer
Number of subjects: 675

Group type: COMPARATOR
Intervention: Patients with clinical T1 through T2 N+ cancer who underwent neoadjuvant therapy plus surgery
Number of subjects: 675

Group type: EXPERIMENTAL
Intervention: Risk factors for occult LNM based on the risk model
Number of subjects: 675

Group type: EXPERIMENTAL
Intervention: Risk scoring system based on the model
Number of subjects: 675
Study: 34736011

Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy (AT)
Number of subjects: 397

Group type: COMPARATOR
Intervention: Watchful waiting with supportive care (WWSC)
Number of subjects: 397
Study: 35532966

Group type: EXPERIMENTAL
Intervention: Web-based, self-administered Stop and Go Switching Task
Number of subjects: 7410

Group type: EXPERIMENTAL
Intervention: Web-based, self-administered Figure Identification test
Number of subjects: 7410
Study: 32846041

Group type: EXPERIMENTAL
Intervention: Bilberry extract (BE) supplementation for 8 weeks
Number of subjects: 0
Study: 35613783

Group type: EXPERIMENTAL
Intervention: PHOENIX intervention
Number of subjects: 375

Group type: COMPARATOR
Intervention: Active control (FRAX questionnaire only)
Number of subjects: 375

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 375
Study: 33608734

Group type: EXPERIMENTAL
Intervention: Genetic liability to insomnia symptoms
Number of subjects: 218379

Group type: COMPARATOR
Intervention: Manifested pain
Number of subjects: 218379
Study: 32054473

Group type: EXPERIMENTAL
Intervention: Targeted lung denervation (TLD) combined with optimal medical therapy
Number of subjects: 400

Group type: COMPARATOR
Intervention: Optimal medical therapy alone
Number of subjects: 400
Study: 34481017

Group type: EXPERIMENTAL
Intervention: RT plus short-term ADT (flutamide with goserelin or leuprolide for 4 months)
Number of subjects: 2028

Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 2028

Group type: EXPERIMENTAL
Intervention: RT plus short-term ADT
Number of subjects: 2028
Study: 34286370

Group type: EXPERIMENTAL
Intervention: Prostatic Artery Embolization (PAE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transurethral Resection of the Prostate (TURP)
Number of subjects: 0
Study: 35894970

Group type: EXPERIMENTAL
Intervention: Electronic format of the IPAB
Number of subjects: 66

Group type: COMPARATOR
Intervention: Pen-and-paper format of the IPAB
Number of subjects: 66
Study: 33757723

Group type: EXPERIMENTAL
Intervention: Insulin (20 U/0.5 mL administered intranasally for 2 days prior to surgery)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (0.5 mL saline administered intranasally for 2 days prior to surgery)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 90
Study: 34427156

Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Endurance and resistance training
Number of subjects: 53
Study: 32494942

Group type: EXPERIMENTAL
Intervention: Experimental group (n=19) received text messages on job openings, educational sessions, mentoring, a start-up grant, and business and HIV prevention text messages.
Number of subjects: 38

Group type: COMPARATOR
Intervention: Comparison group (n=19) received text messages on job openings only.
Number of subjects: 38
Study: 36153560

Group type: EXPERIMENTAL
Intervention: Mobile application
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Digital book
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 210
Study: 32706738

Group type: EXPERIMENTAL
Intervention: REACH text message intervention (daily texts for first 6 months, option to reduce frequency for last 6 months)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: REACH text message intervention with monthly phone coaching for first 6 months
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Participants who continued daily text messages for the last 6 months
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Participants who chose fewer texts
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Engagement analysis
Number of subjects: 248
Study: 36451389

Group type: EXPERIMENTAL
Intervention: Yaobitong capsule
Number of subjects: 258

Group type: COMPARATOR
Intervention: Celecoxib capsule
Number of subjects: 258
Study: 34708639

Group type: EXPERIMENTAL
Intervention: Songlingxuemaikang (SLXMK) 500 mg per capsule, 4500 mg/d, n = 60
Number of subjects: 90

Group type: COMPARATOR
Intervention: Losartan potassium 50 mg per tablet, 50 mg/d, n = 30
Number of subjects: 90
Study: 32041914

Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (NAC) supplementation at 600 mg every 8 hours for 3 days
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard therapy (Control)
Number of subjects: 32
Study: 34360312

Group type: EXPERIMENTAL
Intervention: Diet + Exercise (n = 8)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Diet-only (n = 6)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control/No Intervention (n = 15)
Number of subjects: 29
Study: 35901337

Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy with concurrent temozolomide and adjuvant temozolomide
Number of subjects: 71

Group type: COMPARATOR
Intervention: Short-course radiotherapy alone
Number of subjects: 71
Study: 34429149

Group type: EXPERIMENTAL
Intervention: IV paracetamol (1 g paracetamol + 3.91 g mannitol per 100 mL), n=12
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (0.9% Saline 100 mL), n=12
Number of subjects: 24
Study: 32018030

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rhinovirus-16 inoculation
Number of subjects: 0
Study: 35292490

Group type: EXPERIMENTAL
Intervention: Cognitive tests after each visit with a conversational artificial intelligence bot.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acceptability questionnaires after each visit.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomisation to receive cognitive test results either after each visit or only after completing the study.
Number of subjects: 0
Study: 33539734

Group type: EXPERIMENTAL
Intervention: Chlorhexidine plus alcohol
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Innovation group (closed integrated catheters, positive displacement needleless‐connectors, disinfecting caps, and single‐use prefilled flush syringes)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Povidone iodine plus alcohol
Number of subjects: 1000
Study: 33143764

Group type: COMPARATOR
Intervention: Fasting for 0 days, then refeeding for 14 days
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Fasting for 3 days, then refeeding for 14 days
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Fasting for 7 days, then refeeding for 14 days
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Fasting for 14 days, then refeeding for 14 days
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Fasting for 7 days
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Fasting for 14 days
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Refeeding after fasting
Number of subjects: 120
Study: 33469958

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) intervention
Number of subjects: 4
Study: 36079902

Group type: EXPERIMENTAL
Intervention: NO3‐ supplementation
Number of subjects: 14
Study: 33874993

Group type: EXPERIMENTAL
Intervention: 10 ml levobupivacaine 0.25%
Number of subjects: 48

Group type: COMPARATOR
Intervention: 20 ml levobupivacaine 0.25%
Number of subjects: 48
Study: 32446311

Group type: EXPERIMENTAL
Intervention: Conventional treatment plus Liu‐zi‐jue (a mind‐body exercise)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0